Prime Medicine, Inc. Common Stock (PRME) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Prime Medicine, Inc. Common Stock stock (PRME) is currently trading at $3.52. Prime Medicine, Inc. Common Stock PS ratio (Price-to-Sales) is 139.55. Analyst consensus price target for PRME is $6.92. WallStSmart rates PRME as Sell.
- PRME PE ratio analysis and historical PE chart
- PRME PS ratio (Price-to-Sales) history and trend
- PRME intrinsic value — DCF, Graham Number, EPV models
- PRME stock price prediction 2025 2026 2027 2028 2029 2030
- PRME fair value vs current price
- PRME insider transactions and insider buying
- Is PRME undervalued or overvalued?
- Prime Medicine, Inc. Common Stock financial analysis — revenue, earnings, cash flow
- PRME Piotroski F-Score and Altman Z-Score
- PRME analyst price target and Smart Rating
Prime Medicine, Inc.
📊 No data available
Try selecting a different time range
Smart Analysis
Prime Medicine, Inc. Common Stock (PRME) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in institutional own.. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Prime Medicine, Inc. Common Stock (PRME) Key Strengths (1)
64.40% held by institutions, strong professional interest
Supporting Valuation Data
Prime Medicine, Inc. Common Stock (PRME) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Revenue declining -61.60%, a shrinking business
Very expensive at 139.6x annual revenue
Very expensive at 5.3x book value
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
Prime Medicine, Inc. Common Stock (PRME) Detailed Analysis Report
Overall Assessment
This company scores 15/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 1 register as strengths (avg 8.0/10) while 6 fall into concern territory (avg 1.5/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own..
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Some valuation metrics including Price/Sales (139.55), Price/Book (5.26) suggest expensive pricing. Growth concerns include Revenue Growth at -61.60%, which may limit upside. Profitability pressure is visible in Return on Equity at -146.80%, Operating Margin at -5800.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -146.80% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -61.60% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
PRME Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
PRME's Price-to-Sales ratio of 139.55x trades 49% below its historical average of 271.83x (15th percentile). The current valuation is 81% below its historical high of 717.54x set in Nov 2022, and 95% above its historical low of 71.41x in May 2025. Over the past 12 months, the PS ratio has expanded from ~120.4x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Prime Medicine, Inc. Common Stock (PRME) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Prime Medicine, Inc. Common Stock operates as a stable business with moderate growth and solid fundamentals. Revenue reached 5M with 62% decline year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Spending 749% of revenue (35M) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 62% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -38M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Volatility is elevated with a beta of 2.58, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Prime Medicine, Inc. Common Stock.
Bottom Line
Prime Medicine, Inc. Common Stock offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Prime Medicine, Inc. Common Stock(PRME)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Prime Medicine, Inc. is a pioneering biotechnology firm that aims to transform healthcare with its groundbreaking Prime Editing technology, designed for accurate genetic modifications at the DNA level. The company is advancing a strong pipeline of innovative therapies targeting serious diseases, such as genetic disorders and cancer, backed by exceptional intellectual property protections. Committed to addressing critical unmet medical needs, Prime Medicine is strategically positioned to be a key player in the genetic medicine arena, showing significant potential for growth and a meaningful contribution to the evolving biopharmaceutical landscape.